QTRX:NASDAQ, Quanterix Corporation
QTRX stock overview
Quanterix Corporation (QTRX:NASDAQ) closed at $3.04 on November 4, 2026,
up 3.40% on the day.
The stock trades 65.3% below its 52-week high of $8.77
and 41.4% above its 52-week low of $2.15.
Over the past year, it lost 41.2%.
Quanterix Corporation is part of the Capital Goods sector (Biotechnology: Laboratory Analytical Instruments).
Key figures
- Price
- $3.04
- Day change
- +3.40%
- Volume
- 402,179
- Average volume
- 749,135
- Market cap
- 143M+
- 52-week range
- $2.15 – $8.77
- 50-day average
- $2.99
- 200-day average
- $3.82
Price action over the past year
In 252 trading sessions since November 4, 2025, QTRX closed higher on 110 days (44%).
Its best day was January 9, 2026 (+23.81%) and its worst was August 10, 2026 (-39.95%).
The stock moved 10% or more in a single session 15 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
QTRX news
-
Oct 28, 2026:
Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026
-
Oct 7, 2026:
/C O R R E C T I O N -- ALZpath, Inc./
-
Oct 7, 2026:
ALZpath and Quanterix Expand Strategic Licensing Agreement to Advance Next Generation Alzheimer's Disease Biomarker Research
-
Oct 7, 2026:
Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals
-
Sep 25, 2026:
Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
-
Sep 17, 2026:
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sep 14, 2026:
Quanterix Names Dr. Yuri Fesko Chief Medical Officer
-
Sep 4, 2026:
Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
About Quanterix Corporation
Quanterix Corp is a life science company. The company digitizing biomarker analysis with the goal of advancing the science of precision health.
Similar stocks
Find more stocks like QTRX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.